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Autologous chondrocyte implantation (ACI) has improved outcome in long-term studies of joint repair in
man. However, ACI requires sutured periosteal ﬂaps to secure the cells, which precludes minimally-
invasive implantation, and introduces complications with arthroﬁbrosis and graft hypertrophy. This
study evaluated ACI on a collagen type I/III scaffold (matrix-induced autologous chondrocyte implan-
tation; MACI®) in critical sized defects in the equine model.
Methods: Chondrocytes were isolated from horses, expanded and seeded onto a collagen I/III membrane
(ACI-Maix™) and implanted into one of two 15-mm defects in the femoral trochlear ridge of six horses.
Control defects remained empty as ungrafted debrided defects. The animals were examined daily, scored
by second look arthroscopy at 12 weeks, and necropsy examination 6 months after implantation. Re-
action to the implant was determined by lameness, and synovial ﬂuid constituents and synovial mem-
brane histology. Cartilage healing was assessed by arthroscopic scores, gross assessment, repair tissue
histology and immunohistochemistry, cartilage glycosaminoglycan (GAG) and DNA assay, and mechan-
ical testing.
Results: MACI® implanted defects had improved arthroscopic second-look, gross healing, and composite
histologic scores, compared to spontaneously healing empty defects. Cartilage GAG and DNA content in
the defects repaired by MACI implant were signiﬁcantly improved compared to controls. Mechanical
properties were improved but remained inferior to normal cartilage. There was minimal evidence of
reaction to the implant in the synovial ﬂuid, synovial membrane, subchondral bone, or cartilage.
Conclusions: The MACI® implant appeared to improve cartilage healing in a critical sized defect in the
equine model evaluated over 6 months.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Extensive cartilage injuries frequently occur during sporting
activities and often culminate in osteoarthritis (OA). Even focal
impact to cartilage can have long term deleterious effects, largely
due to the limited potential to initiate repair from the avascular and
poorly cellular architecture of adult hyaline cartilage. Focal defects
can negatively affect the cartilage surrounding them, and may lead
to joint pain and eventual degenerative OA. In the United Statesto: A.J. Nixon, Comparative
ences, College of Veterinary
ternational. Published by Elsevier Lalone, over 27 million people suffer from OA, and annual medical
costs associated with OA management exceed $60 billion.1,2
Methods to improve cartilage repair compensate for intrinsic
deﬁciencies, and include marrow stimulating techniques, implan-
tation of autologous or allograft osteochondral dowels or larger
shell grafts, and for the past 25 years, autologous chondrocyte
implantation (ACI)3e6. Increasingly, extensive cartilage lesions are
often assigned to ACI or allograft osteochondral transplantation5,7,8.
These procedures have been associated with improved outcome
after extensive injury5,7,9e11.
ACI in the knee has provided sustained success in long-term
studies12,13. Second and third generation ACI techniques take
advantage of other membranes to retain autologous chondrocytes
in the cartilage defect (second generation), or inﬁltrate cells intotd. All rights reserved.
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cally (third generation)14,15. The results of clinical trials using sec-
ond and third generation ACI techniques are not as extensive as
those associated with the original ACI. However, improvement in
clinical outcome has varied from 70 to 80% in repair of cartilage in
the knee15e18.
The Matrix-induced autologous chondrocyte implantation
(MACI®) implant utilizes a porcine collagen I/III membrane (ACI-
Maix™; Genzyme, a Sanoﬁ company), seeded with autologous
chondrocytes. It differs in origin to porcine small-intestine (SIS)
based membranes, evaluated previously in equine models19. MACI
has been evaluated in several animal studies, where it has been
shown to improve repair in full thickness cartilage lesions20,21.
Reaction to the membrane alone has also been evaluated and found
to produce minimal immune or inﬂammatory responses20e22.
Studies using MACI® for cartilage repair in the human knee have
been positive with well tolerated implants and improved func-
tion16,23,24. Case selection for the MACI® implant has generally
followed similar guidelines to selection of patients for ACI, target-
ing large complex full-thickness cartilage lesions, and those that
had failed previous therapies. The novel aspects of MACI® include
the elimination of suturing of the graft into the cartilage defect25,
the potential for arthroscopic insertion, and the decreased adverse
bioactive potential for vasculogenic hypertrophy14,15. Use of bio-
logic ﬁbrin based glues has allowed mini-arthrotomy or arthro-
scopic implantation of press-ﬁt grafts, with limited biologic gluing
of the base and perimeter, and facilitated chondrocyte migration
from the membrane to the healing tissue26,27.
There are a paucity of experimental studies to establish the
survival and efﬁcacy of the MACI® implant for cartilage repair20,21.
This study was designed to evaluate implant retention and efﬁcacy
of the MACI® implant in a large animal model, using autologous
chondrocytes implanted after in vitro culture on a collagen I/III
(ACI-Maix™) membrane. Control defects were allowed to heal
spontaneously.
Methods
Chondrocyte isolation and propagation
Four weeks prior to scheduled MACI® implantation, cartilage
biopsies were obtained arthroscopically from the femoral trochlear
ridge of six young mature horses, aged two to 6 years. Cartilage
biopsies (1e2 gm) were enzymatically digested, expanded in vitro,
and seeded on collagen type I/III membranes (ACI-Maix™; Gen-
zyme Corp), using 0.9 to 1.1 million chondrocytes per cm2. Mem-
branes were incubated for 48 h prior to shipping.
Experimental design
Cartilage defects were formed in one femoropatellar joint of all
six horses. In each horse, two 15-mm diameter full thickness
cartilage defects were formed in the lateral trochlear ridge of the
femur in the patellofemoral joint of one randomly selected limb.
One of these defects was repaired with a chondrocyte seeded
MACI® implant. The second defect remained empty to heal
spontaneously.
Surgical implantation procedure
Horses were anesthetized and a femoropatellar joint mini-
arthrotomy performed. Perioperative pain control included sacro-
caudal vertebral morphine and detomidine epidural injection. The
femoropatellar joint contralateral to the joint previously randomly
selected for cartilage biopsy was implanted. Joint ﬂuid waswithdrawn and analyzed for a cell count, protein content, and PGE2
assay. A 5e6 cm mini-arthrotomy was made between and parallel
to the middle and lateral patellar ligaments. With the limb fully
extended, a 15-mmvertical walled defect wasmade in the proximal
aspect of the lateral trochlear ridge using a skirted custom bit with
rigid guide cannula. Uncalciﬁed and calciﬁed cartilage were
removed down to the subchondral bone. A calibrated probe was
used tomeasure the depth of the defect at four locations around the
perimeter. A second defect was formed distal to the initial defect,
with 1 cm separating the two, utilizing limb ﬂexion to expose
additional lateral trochlear ridge (Fig. 1). Both defects had exposed
subchondral bone without violating the dense subchondral bone
plate.
A 17 mm circular implant was dissected from the 4  6 cm
chondrocyte-seeded collagen type I/III membrane, taking care to
identify the rough surface which had been inﬁltrated with chon-
drocytes. Implantation of the MACI® membrane was randomly
assigned to the proximal and distal defects within the joint for the
six horses. The rough surface of the MACI® implant was inserted
facing downward to contact the subchondral bone (see Fig. 1). Once
in position in the cartilage defect, the edge of the membrane was
gently raised and thrombin activated ﬁbrin (Tisseel™, Baxter
Healthcare) was injected into the interface between subchondral
bone and membrane. The edges of the membrane were then gently
press ﬁt and a ﬁnal seal of ﬁbrin injected around the entire
perimeter. The arthrotomy incision was sutured in ﬁve layers. The
horses recovered from anesthesia without limb coaptation, since
immobilization of this joint can not be readily accomplished. Ex-
ercise was limited to complete stall conﬁnement for the initial
4 weeks and then brief walking for an additional 6 weeks, before
gradual introduction of small paddock exercise.
Lameness exams were performed prior to entering the study,
prior to implantation surgery, immediately prior to second look
arthroscopy at 3 months post implantation, and at the completion
of the study at 24 weeks.
Chondrocyte viability
Residual cell membrane remaining immediately after surgery
was assessed for chondrocyte viability using ﬂuorescein diacetate
and propidium iodide uptake under high power confocal
microscopy.
Second look arthroscopy
At 12 weeks post implantation, all horses were re-anesthetized,
synovial ﬂuid sampled, and the healing cartilage defects in the
implanted stiﬂe were assessed arthroscopically for repair tissue
color and smoothness, defect ﬁlling, perimeter integration, sub-
chondral bone attachment, and pannus formation. Each parameter
was assigned a score, and the scores tallied for each implant type.
The opposite femoropatellar joint was examined, biopsy sites
assessed, and a synovial biopsy obtained.
Tissue harvest and analysis
All horses were euthanized 6 months after implantation, and
the treated and biopsy joints examined. Synovial ﬂuid was
retrieved from both patellofemoral joints, and the cartilage scored
for macroscopic evidence of healing. Scores were assigned for
defect ﬁll, repair tissue color, surface smoothness, integration with
surrounding cartilage, integration to the subchondral bone, and
presence of pannus. The repair tissue was then sagittally divided
into thirds, using the central 3 mm osteochondral block for his-
tology, cartilage from an adjacent third of the surface for
Fig. 1. Arthrotomy and 15 mm defect formation. (A) Proximal and distal defects have been formed. (B) MACI implant is inserted. (C) Fibrin gluing membrane in defect. (D) Final
ﬁbrin sealant and drying.
A.J. Nixon et al. / Osteoarthritis and Cartilage 23 (2015) 648e660650biochemical assays, and the lateral osteochondral block for
biomechanical testing of 6 mm core samples. Samples were
retrieved from identical locations in the opposite femoropatellar
joint to serve as normals for histology, biochemical, andmechanical
assays.
Histology
The osteochondral samples were ﬁxed in 4% paraformaldehyde,
decalciﬁed in 10% ethylenediaminetetraacetic acid (EDTA), and high
resolution radiographic examination used to assess subchondral
bone structure. The samples were then dehydrated, cleared,
embedded in parafﬁn, and sectioned at 6 mm. The sections were
stained with hematoxylin and eosin to evaluate morphology, and
toluidine blue to assess proteoglycan (PG) distribution in the per-
icellular matrix. Sections for collagen immunohistochemistry were
treated with 5 mg/ml hyaluronidase, and rat anti-bovine type II
collagen primary antibody or rabbit anti-equine type I collagen
primary antibody applied for 60 min. Secondary biotinylated goat-
anti-rat antibody (type II) or goat anti-rabbit antibody (type I) was
applied, followed by streptavidin conjugated peroxidase to catalyze
chromogen development in 3,30-diaminobenzidine tetrachloride.
Sections were counter-stained with hematoxylin, and examined by
microscopy to determine type I and type II collagen distribution.
Control samples for type II were derived from equine costochondral
junctions, using the cartilaginous portion as positive and the
spongiosa as negative control.
Slides were examined blinded by two observers and a score for
defect healing was derived using published parameters to develop
a composite score28. These parameters include scores for defect ﬁll,chondrocyte predominance, chondrocyte cloning, perimeter inte-
gration, subchondral bone attachment, extent of tidemark refor-
mation, surface ﬁbrillation, and additional scores for the depth of
toluidine blue matrix staining and collagen type II predominance.
These were summed to develop a ﬁnal score. Data for histologic
scoring was analyzed to compareMACI® implant defects to controls
where the defects were left empty.
PG and DNA analysis
Cartilage was pulverized at 196C in a freezer mill, followed by
lyophilization and digestion in papain. Total glycosaminoglycan
(GAG) in repair tissue from chondrocyte implanted and control
cartilage lesions in each joint was assayed by the dimethyl-
methylene blue dye binding (DMMB) microplate assay on a 96-well
microplate reader.
Total DNA was determined on duplicate 10 ml aliquots of papain
digest incubated for 24 h at 65C. The samples (10 ml) were mixed
with bisbenzimide compound for DNA quantiﬁcation by ﬂuoro-
metric assay.
Synovial ﬂuid analysis
Total and differential cell counts, and synovial ﬂuid smear
analysis, were performed on serial samples of ﬂuid by routine
Coulter counting and assessment of Giemsa-stained smears,
respectively. PGE2 analysis was performed using a commercial
ELISA reagent kit (Assay Designs, Enzo Lifesciences, Ann Arbor, MI).
Synovial ﬂuid samples were precipitated with ethanol and acetic
acid, centrifuged, and the supernatant was applied to a C18 reverse
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A.J. Nixon et al. / Osteoarthritis and Cartilage 23 (2015) 648e660 651phase column for extraction. PGE2 was eluted from the columns
with 100% ethyl acetate, dried, and the residual sample assessed by
ELISA using manufacturer's instructions.
Biomechanical analysis
Osteochondral plugs (6 mm cores) were trimmed to leave
0.6 mm bone attached to the base, precisely recut to 3 mm cores
with a biopsy punch, and evaluated by unconﬁned, uniaxial
compression testing, using a step-wise stress relaxation protocol
(Mach1™ Mechanical Loading Unit; BioSyntech Ltd.). A ﬁbril-
reinforced biphasic model was used to determine values for
permeability (k), equilibrium matrix modulus (Em), and the ﬁbril
network modulus (Ef)29. A customized MATLAB®-based software
program developed by BioSyntech Ltd. was used to ﬁt the data to
the model.
Statistical analysis
Random distribution of continuous data was assessed by the
ShapiroeWilk normality test. Comparison of the synovial ﬂuid data
between treated and biopsied joints, and biochemical data from the
treated and control defects was determined by Student's t test.
Ordinal data (arthroscopic second look, gross, and histologic scores)
were analyzed using Wilcoxon Rank Sum test when comparing
MACI® implant to empty controls. Permeability, equilibriummatrix
modulus, and ﬁbril network modulus results were compared
among treated and control groups using TukeyeKramer HSD
analysis. A P value 0.05 was considered statistically signiﬁcant.
Results
Chondrocyte viability
Residual MACI® membrane was examined by histology, and
viable other portions stained in ﬂuorescein and propidium iodide
to evaluate cell distribution and cell viability. ACI-Maix membrane
surface loading was good (Supplementary Material), and viability
excellent. Rare small subcellular DNA aggregates were identiﬁed on
the cell membrane surface (red ﬂuorescing fragments).
Clinical ﬁndings
The arthrotomy incision healed by primary intention in all
horses. There was no evidence of lameness in any horse at any time
point. At 6 months, no horse showed evidence of lameness or
palpable defect at the surgical site.
Synovial ﬂuid analysis
Synovial ﬂuid samples retrieved at implantation surgery, at 12
week second look arthroscopy, and at termination 24 weeks after
implant were assessed. Protein content and cell counts were
normal before surgery for our laboratory, and were normal or
slightly increased at 12- and 24-weeks after implantation (Table I).
The data was normally distributed. There were no signiﬁcant dif-
ferences for joints implanted with MACI® and opposite control
joints used for cartilage biopsy. No evidence of lymphocytic or
eosinophilic response was present.
PGE2 analysis
Synovial ﬂuid PGE2 concentration in synovial ﬂuid samples
collected at second look arthroscopy (3months) and termination (6
months) post-implantation from treated (MACI implant) and
A.J. Nixon et al. / Osteoarthritis and Cartilage 23 (2015) 648e660652control (biopsy) joints was determined using ELISA. At 3 months,
PGE2 concentration was higher in treated joints compared to
opposite control joints (implanted mean 24.57 pg/ml with 95%
conﬁdence interval (CI) 17.70e31.45 pg/ml; control 16.46 pg/ml
with CI 14.18e18.74; P ¼ 0.03). At 6 months post-implantation,
PGE2 levels had risen further in both treated and control joints,
and treated joints had increased PGE2 compared to controls
(implanted 35.91 pg/ml, CI 22.20 to 49.61; control 22.75 pg/ml, CI
20.97 to 24.54; P ¼ 0.05). Treated and control joints had signiﬁ-
cantly higher PGE2 concentrations at 6 months post-implantation
compared to 3 months post-implantation (treated P ¼ 0.0300,
control P ¼ 0.0028).
Arthroscopic second look
Cartilage repair tissue was assessed at 12 weeks by arthroscopic
examination and scoring (Table II). The composite score for MACI®
implanted defects (mean 5.33; CI 3.75e6.91) was signiﬁcantly
improved compared to empty defects (mean 9.17 with CI
4.05e14.28). There was signiﬁcant improvement for surface
smoothness in MACI® implant defects and a trend (P > 0.05 and
<0.1) toward improved scores for percent ﬁll, perimeter integra-
tion, and tissue color (Supplementary Material).
Gross appearance
MACI® implanted defects had signiﬁcantly improved scores for
graft perimeter and base integration to cartilage and subchondral
bone respectively (Table III). Total score for MACI® implanted de-
fects (4.67 with CI 1.37e7.96) and control defects (7.00 with CI
3.00e11.02) were not different (P ¼ 0.065), despite the trend
(P < 0.1). None of the implanted MACI® membranes appeared to
have dislodged, and no fragments were evident in the synovial
recesses of the joint.
High detail radiographs
There were no subjective differences in the extent of sub-
chondral bone lysis or intrusion into the cartilage repair tissue
evident on high resolution radiography. Many horses had variable
subchondral radiolucency across the specimen width. This wasTable II
Arthroscopic second look repair cartilage scores at 12 weeks. Within each parameter zer
means and 95% CI. P values indicate signiﬁcant differences (P  0.05) and trends (0.05 >
Defect
treatment
Smooth white
repair tissue
(0e3)
Percent ﬁlling
(0e4)
Repair tissue
perimeter
integration (0e4)
Repair tissue
integration (
MACI (n ¼ 6) 1.00 (0.34e1.67) 1.00 (0.06e1.94) 0.17 (0.26e0.60) 0.0 (0.0e0.0)
Ungrafted
(n ¼ 6)
2.00 (1.06e2.94) 2.00 (0.52e3.48) 0.67 (0.60e1.94) 0.33 (0.52e
P value 0.054 0.102 0.102 0.182
Table III
Gross healing scores at 24 week termination. Data presented as means and 95% CI. Total s
(P  0.05) and trends (0.05 > P < 1.0)
Defect
treatment
Percent ﬁlling
(0e4)
Smooth white
repair tissue
(0e3)
Repair tissue
perimeter
integration
(0e4)
Repair tissu
integration
MACI (n ¼ 6) 0.83 (0.14e1.81) 1.17 (0.45e1.88) 0.17 (0.26e0.60) 0.17 (0.26
Ungrafted
(n ¼ 6)
1.17 (0.14e2.20) 1.17 (0.14e2.20) 1.08 (0.18e2.34) 0.67 (0.19
P value 0.272 1.00 0.039 0.038similar in MACI® and spontaneously healing defects. Similarly,
there was no difference between and the proximal and distal
location for subchondral bone radiolucency.Histologic appearance
Cartilage ﬁlling was improved in MACI® implanted defects, and
repair tissue attachment to subchondral bone at the base and to
surrounding cartilage were often better with MACI® implant
(Fig. 2). Islands of new cartilage developed in areas beneath MACI®
membrane (Supplementary Material). No cartilage formed super-
ﬁcial to the membrane. Defects allowed to spontaneously heal, had
thinner repair tissue, and many had separation of the repair tissue
from the underlying bone (Fig. 2). Scores were assigned using
previously published parameters, and data are presented in
Table IV. MACI® improved many of the indices used to assess his-
tologic integrity, compared to empty defects. Total composite
scores showed MACI® implanted defects (17.88 with CI
13.42e22.33) were signiﬁcantly improved (P ¼ 0.046) compared to
empty control defects (21.5, CI 19.20e23.81).Collagen type II abundance
Collagen type II immunohistochemical reaction revealed occa-
sional improvements in collagen type II content in MACI®
implanted defects (Fig. 3). However, collagen type II abundancewas
variable and MACI® implant defects were not statistically different
than empty controls (see Table IV). Collagen type II predominated
in the base and middle portions of the healing cartilage. Consistent
ﬁndings were increased extent of type II deposition throughout the
healing tissue, but less focally intense reaction adjacent to the
subchondral bone (Fig. 3). Additionally, chondrocytes embedded
deep within the residual MACI® ﬁber network were not strongly
positive for type II collagen accumulation in the territorial matrix
(Fig. 4). Both implanted and empty defects were considerably less
positive for collagen type II than normal opposite limb sections (see
Figs. 3 and 4). Additionally areas within the defect tissue attached
to the perimeter intact cartilage had increased type II content.
Several areas had microscopic evidence of residual collagen type I/
III ﬁber.o ¼ normal. Total score range 0 ¼ normal; 23 ¼ poorest healing. Data presented as
P < 1.0)
base
0e3)
Tissue color (0e4) Tissue softness
(0e3)
Pannus (0e2) Total (0e23)
1.67 (1.12e2.21) 1.50 (0.93e2.07) 0.00 (0.0e0.0) 5.33 (3.75e6.91)
1.19) 2.33 (1.25e3.42) 1.83 (1.04e2.62) 0.00 (0.0e0.0) 9.17 (4.05e14.28)
0.087 0.182 1.0 0.050
core range 0 ¼ normal; 23 ¼ poorest healing. P values indicate signiﬁcant differences
e base
(0e3)
Tissue color (0e4) Tissue softness
(0e3)
Pannus (0e2) Total (0e23)
e0.60) 1.17 (0.10e2.44) 1.17 (0.50e1.88) 0.00 (0.0e0.0) 4.67 (1.37e7.96)
e1.52) 1.67 (0.75e2.59) 1.25 (0.81e1.70) 0.00 (0.0e0.0) 7.00 (3.00e11.02)
0.241 0.404 1.00 0.065
Fig. 2. (A) Photomicrograph of composite image of the healed 15 mm diameter MACI implanted defect. Bar ¼ 1 mm. Defect is completely ﬁlled with new tissue, and has integrated
to surrounging cartilage (left inset box). Areas of original MACI membrane (mid inset box) and induced cartilage deep to residual ACI-Maix fragments are shown. More carti-
laginous regions have developed deep in the healing cartilage (right inset box). Base separation is intermittent and surrounding attachment to cartilage is good. (B) Histologic
appearance of control defect showing poor basal integration of repair tissue with subchondral bone. Integration to surrounding cartilage is incomplete (left inset), and severe
chondron formation (clones) has developed in original cartilage on right junction (right inset). Deeper regions of the cleft show minor cartilage development (mid inset box).
Bar ¼ 1 mm. H&E stain.
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Compared to the type II predominance in the middle and deeper
zones of cartilage, collagen type I appeared to be evenly distributed
throughout the healing tissue. Additionally, evidence of moderate
collagen type I formation extended to the surface of the healing
defects and in many samples onto the surface of the adjacent
normal cartilage.
Toluidine blue histochemistry
The depth of toluidine stained matrix was occasionally more
extensive in MACI® implanted defects (Fig. 5), but these were
inconsistent and scoring data showed few differences in PG depo-
sition (see Table IV). None of the implanted or control defects had
complete histochemical reaction across the full depth of the repair.
The deeper regions of MACI® implanted defects had a preponder-
ance of toluidine stained matrix.
Synovial membrane histology
Synovial membrane biopsy at second-look arthroscopy at 3
months showed statistically signiﬁcant changes in the synovial
membrane from MACI® treated joints (Table V), compared to con-
trol (biopsy) joints for total cumulative score and inﬂammatory cell
inﬁltrate (perivascular cufﬁng). Minor differences in subintimal
ﬁbrosis and intimal layer thickening added to the cumulative dif-
ference (Supplementary Material). By 6 months, synovial mem-
brane scores were similar between MACI® implanted and opposite
control joints and most scored within normal ranges (Table V).
Minimal perivascular mononuclear WBC accumulations persisted
in MACI® implanted joints in ﬁve of the six horses, but these dif-
ferences did not reach statistical differences compared to control
joints.
Biochemical characterization
Cartilage GAG and DNA were analyzed in defect repair tissue.
GAG levels were signiﬁcantly higher (P ¼ 0.003) in the repair tissue
of MACI® implant defects compared to the control defects (see
Fig. 5(B)). DNA content was also signiﬁcantly higher (P ¼ 0.035) in
repair tissue from treated defects compared to controls.
Biomechanical evaluation
Equilibrium matrix modulus (Em) and ﬁbril network modulus
(Ef) results for the MACI® treated group trended higher compared
to the empty defect (control) group [Fig. 5(C),(D)], but these dif-
ferences were not statistically signiﬁcant (TukeyeKramer HSD,
P > 0.05). The nonsurgical control group from the opposite femo-
ropatellar joint were signiﬁcantly more resilient (TukeyeKramer
HSD, P < 0.05) than both the MACI treated and empty defect
(control) groups. Permeability (k) values for the nonsurgical control
group were signiﬁcantly lower (TukeyeKramer HSD, P < 0.05) than
the empty defect (control) group but not signiﬁcantly different
(TukeyeKramer HSD, P > 0.05) from the MACI treated group
[Fig. 5(E)]. There was no statistical difference (TukeyeKramer HSD,
P > 0.05) between the empty defect (control) and MACI groups for
this parameter.
Discussion
Repair of full-thickness cartilage defects with the MACI®
implant improved cartilage quality compared to empty defects.
Interim arthroscopic assessment 3 months following implantation
revealed improved repair tissue appearance, which persisted to the
Fig. 3. Collagen type II deposition 6 months post-implantation. MACI implant defect (top row), non-immune serum immune control on MACI defect (middle row left), and empty
control defect (middle row, center and right). MACI membrane remains in the center regions, where most cells express collagen type II. Collagen density increases toward the
deeper regions of the defect. Empty defect show a typical thin region of collagen type II deposition in the base of defect. Normal reaction is shown in costochondral junction (lower
left), and normal control cartilage from the opposite limb reacted with anti-collagen type II Ab (lower middle) or non-immune serum (lower right). Bar ¼ 50 mm.
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and cartilage biochemical composition was better. Repair tissue
was thicker and better integrated to underlying bone when probed,
and combined with increased cartilage GAG and DNA content, was
a superior quality repair tissue compared to cartilage defects that
were allowed to heal spontaneously. These ﬁndings strengthen the
limited previous studies in smaller animal species, which showed
improved tissue repair in short term studies of the MACI®
implant20,21. Comparison of healing to microfractured empty de-
fects would also have been useful in the current study, although the
indications for MACI and microfracture are disparate, with MACI
being preferred in challenging and previously failed lesions.
The MACI® implant provides several advantages over the orig-
inal ACI procedure, including provision of a stabilizing collagen
type I/III scaffold, eliminating the need for suture retention of the
membrane, avoiding the harvest and implantation of vasculogenic
periosteum with potential hypertrophic complications, andimproving the environment for chondrogenesis15. These in-
novations may expedite the surgery and potentially improve the
quality of cartilage repair.
The collagen type I/III membrane is a mixed collagen type I and
type III porcine derived membrane which has been well charac-
terized by both in vitro and in vivo trials20,21,30e33. The processed
collagen type I/III membrane has been shown to be a porous,
coarsely ﬁbrillar, scaffold, that has a smooth resilient surface and a
rough porous surface31,32,34e36. Chondrocytes are loaded onto the
rough surface during manufacture, using chondrocyte densities of
0.5e2  106 cells per cm2 of membrane. The collagen type I/III
membrane is generally populated with autologous chondrocytes
48 h prior to shipment for MACI® implant surgery.
The MACI® implant was well tolerated in this study, despite the
porcine collagen I/III xenograft origin. Serial synovial ﬂuid analyses
and biopsy retrieval of synovial membrane at 3 months showed
minor differences compared to the unimplanted joint from the
Fig. 4. Collagen type II in MACI implanted defect (top row), empty control defect (middle row), and normal control cartilage (bottom row) reacted with anti-collagen type II Ab (left)
or non-immune serum (right). MACI membrane has been resorbed in all regions, and most cells in the deeper layers are surrounded by type II Collagen. Empty defect shows typical
thin region of collagen type II deposition in base of defect. Bar ¼ 40 mm.
A.J. Nixon et al. / Osteoarthritis and Cartilage 23 (2015) 648e660656opposite limb. Synovial ﬂuid nucleated cell counts were similar
between implanted and naïve joints at 3 months and the propor-
tion of macrophages and lymphocytes in joint ﬂuid was similar
between treated and controls. Minor perivascular lymphocyticFig. 5. A) Toluidine blue histochemical characterization of PG deposition in healing defects
rich territorial and interterritorial PG-rich matrix. Sparse toluidine stained matrix is presen
repair tissue. Bar ¼ 200 mm. (BeE) Dot density plots showing biochemical and biomechan
GAG and DNA content on a dry matter basis of repair cartilage harvested from defects at 6 m
and control. Biomechanical assessment indicated MACI® trended toward an improvement fo
compared to spontaneously healing defects, but values were signiﬁcantly inferior to intactaccumulation in the synovial membrane sections had resolved by 6
months. All other synovial membrane features such as intimal
thickening, vascularity, and ﬁbrosis were similar between implan-
ted joints and normal opposite limb joints. The extent of persistingshowing extensive deep repair tissue PG layers in MACI® implant sample. Inset shows
t in spontaneously healing repair. Inset shows minimal PG deposition around base of
ical characteristics of MACI and ungrafted controls compared to normal cartilage. (B)
onths. P values are derived from a paired t-test and indicate differences between graft
r the compressive matrix modulus (C), ﬁbril network modulus (D), and permeability (E)
cartilage from opposite femoropatellar joints. (Mean ± 95% CI).
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Table V
Synovial membrane histologic scores at biopsy at 12 weeks second look and at termination 24 weeks after implantation. Lower scores are more normal. Data presented as
means and 95% CI. Total Min ¼ 0 Max ¼ 15. Statistical signiﬁcance within each parameter is indicated by P  0.05
Joint Villus architecture
(0e3)
Villus subintimal
ﬁbrosis (0e3)
Intimal layer
thickening (0e3)
Vasculature
(number of vessels) (0e3)
Inﬂammatory cell inﬁltrate
(perivascular cufﬁng) (0e3)
Total (0e15)
Treated joint 3 mth (n ¼ 6) 0.48 (0.19e1.16) 1.05 (0.45e1.65) 0.12 (0.18e0.42) 1.10 (0.67e1.54) 1.17 (0.28e2.06) 3.92 (2.39e5.44)
Unoperated control3 mth
(n ¼ 6)
0.12 (0.18e0.42) 0.45 (0.15e1.05) 0.0 (0.0e0.0) 0.68 (0.07e1.44) 0.0 (0.0e0.0) 1.22 (0.06e2.37)
P value 0.309 0.073 0.363 0.244 0.020 0.029
Treated joint 6 mth (n ¼ 6) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.0 (0.0e0.0) 0.58 (0.19e0.98) 0.58 (0.19e0.98)
Unoperated control6 mth
(n ¼ 6)
0.17 (0.26e0.60) 0.0 (0.0e0.0) 0.33 (0.21e0.88) 0.17 (0.26e0.60) 0.08 (0.13e0.30) 0.75 (0.31e1.19)
P value 1.00 1.00 0.455 1.00 0.054 0.535
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wasminimal, with short ﬁbrils (see Fig. 3) being found in four of the
six defects implanted with MACI®. This is consistent with other
studies, which suggest that the collagen I/III membrane is actively
resorbed from 3 to 6 months after implantation20.
Results of MACI® implant treatment of clinical focal cartilage
defects in man have been published, spanning post-operative pe-
riods from ﬁve to 10 years37e41. The clinical beneﬁt:risk ratio of
MACI®, combined with the results of this medium-term study in a
large animal model, support the use of MACI® for cartilage repair. It
provides technical improvements, including suture-less insertion,
propensity for minimally invasive application, and a secure delivery
through a self-contained chondrocyte-laden membrane that can be
cut to approximate the defect dimension and secured with a ﬁbrin
sealant15,41. Surgery times and morbidity may be less using MACI®
rather than ACI with periosteal ﬂap retention, and outcome has
been at least equivalent41,42. These features may improve physician
and patient interest in MACI® and reduce costs to insurance
carriers.
Biochemical analysis of the repair cartilage showed improved
PG and DNA content in MACI® grafted defects compared to
spontaneously healing defects. PG quantitative assays show a
positive impact of the chondrocytes in the supporting membrane.
DNA content of the healing tissue after MACI® implant indicated
the defects were more cellular than those that were allowed to
spontaneously heal. More organized histology and improved PG
content are important milestones, especially given the relatively
long term nature of this study and the size of the experimental
defects.
Improved repair tissue bulk, chondrocyte distribution, and
matrix composition in MACI® implant treated cartilage defects,
supports clinical data which shows improved cartilage quality in
biopsy information from MACI® implant defects in the knee16,37,42.
Utilization of the MACI implant in this medium term study did not
result in hyaline cartilage, but did have an impact in driving tissue
regrowth and cartilage GAG increases. Longer term studies will be
required to determine the extent of hyaline cartilage formation in
experimental defects. It seems the primary role of the collagen type
I/III membrane was as a supportive scaffold and delivery vehicle for
chondrocyte implantation, to provide a chondrocyte population
that could then proliferate in the base of the membrane and the
interface between the debrided bone and the MACI® implant.
Chondrocytes have been shown to readily migrate into the inter-
face region26, to then begin the cartilage healing process in the
depths of the defect. Patient biopsy information from MACI® re-
pairs in the knee suggest hyaline cartilage forms in 36% of patients
within a year of MACI® repair42. Additionally, high resolution
magnetic resonance imaging (MRI) also indicated MACI® repair
tissue developed a normal cartilage signal in 13 of 20 patients
examined up to 1 year after implant43.The equine model was selected to provide a critical sized defect
(15 mm) that also provided ample tissue for multiple types of
analysis. The equinemodel is potentially themost closely aligned to
the challenges of cartilage healing in man44. The thickness of
equine cartilage, including the thickness of the calciﬁed cartilage is
similar to that in man, and thicker than any other animal typically
used for experimental studies of cartilage repair45. Critical sized
defects in the equine femoral trochlear and condyle models are
reported to be around 6e9 mm46,47, and studies using defects
12e15 mm in diameter have been discriminatory in establishing
efﬁcacy28,48,49.
The limitations of this study include the inﬂuence of healing in
one defect on the adjacent defect within the same joint. As such the
inﬂuence of the MACI implant on the spontaneously healing defect,
positive or adverse, can not be separated. Additionally, the inﬂu-
ence of the MACI implant on synovial membrane and synovial ﬂuid
characteristics were compared to normal opposite limb patellofe-
moral joint data, which controls for inter-animal variability but
does not allow separation of the inﬂuence of the empty surgical
defect compared toMACI implant repaired defects on synovial ﬂuid
or synovial membrane characteristics. Previous studies in this
model indicate any surgical procedure has short term (7e14 day)
but not long term impact on synovial ﬂuid parameters, and negli-
gible inﬂuence on synovial membrane appearance beyond 12
weeks48,49.
In conclusion, the MACI® implant resulted in improved cartilage
repair, with a more robust and PG rich repair cartilage, compared to
empty defects. The impact of the MACI® implant on matrix quality
was clearly evident in the middle and deep zones of the repair, and
in the integration with the subchondral bone. Overall, the MACI®
implant improved many of the parameters consistent with durable
cartilage healing, while showing few safety concerns including
resolution of synovial membrane perivascular cufﬁng and return of
synovial ﬂuidWBC counts to normal by 6 months. These data ratify
positive clinical data derived from MACI® implant in full thickness
lesions of the knee, and suggest a mechanism for improved repair
in clinical patients.
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